Literature DB >> 31765029

Isotretinoin-induced sacroiliitis: Case series of four patients and a systematic review of the literature.

Şerife Gül Karadağ1, Hafize Emine Sönmez1, Ayşe Tanatar1, Mustafa Çakan1,2, Nuray Aktay Ayaz1.   

Abstract

Isotretinoin is the mainstay treatment in severe acne; however, its musculoskeletal adverse effects such as lower-back pain can be disabling. Herein, we present four cases of isotretinoin-induced sacroiliitis with variable severity. We also present a review of the literature of isotretinoin-induced sacroiliitis. All our cases were male and human leukocyte antigen (HLA)-B27 negative. Sacroiliitis was detected a median of 55 (10-120) days after isotretinoin initiation. Two patients were responsive to baseline sulfasalazine and indomethacin treatment, while the other two patients required more intensive treatments: adalimumab in one and methotrexate in the other. We also identified 15 articles describing 33 patients (17 of whom were female) with isotretinoin-induced sacroiliitis. Most of them were responsive to low-to-medium doses of systemic steroids or non-steroidal anti-inflammatory drugs (NSAIDs). Our patients illustrate that severity of isotretinoin-induced sacroiliitis varies from patient to patient.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  acne vulgaris; isotretinoin; sacroiliitis

Year:  2019        PMID: 31765029     DOI: 10.1111/pde.14035

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  2 in total

1.  Evaluation of musculoskeletal adverse effects in patients on systemic isotretinoin treatment: A cross-sectional study.

Authors:  Emine Müge Acar; Senem Şaş; Fatmanur Aybala Koçak
Journal:  Arch Rheumatol       Date:  2021-12-24       Impact factor: 1.007

2.  A patient with chronic sacroiliitis undiagnosed for three years after isotretinoin use.

Authors:  Cevriye Mülkoğlu; Barış Nacır
Journal:  BMC Musculoskelet Disord       Date:  2020-05-14       Impact factor: 2.362

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.